Your browser is no longer supported. Please, upgrade your browser.
NERV Minerva Neurosciences, Inc. daily Stock Chart
NERV [NASD]
Minerva Neurosciences, Inc.
Index- P/E- EPS (ttm)-0.70 Insider Own0.10% Shs Outstand39.48M Perf Week-0.90%
Market Cap132.29M Forward P/E- EPS next Y-0.81 Insider Trans-3.22% Shs Float35.75M Perf Month8.22%
Income-26.50M PEG- EPS next Q-0.23 Inst Own68.00% Short Float9.91% Perf Quarter-9.37%
Sales41.20M P/S3.21 EPS this Y-43.10% Inst Trans0.37% Short Ratio4.80 Perf Half Y-62.36%
Book/sh1.44 P/B2.28 EPS next Y-8000.00% ROA-32.80% Target Price- Perf Year-20.34%
Cash/sh0.88 P/C3.75 EPS next 5Y- ROE-66.70% 52W Range1.81 - 15.22 Perf YTD-53.73%
Dividend- P/FCF- EPS past 5Y16.20% ROI- 52W High-78.38% Beta1.50
Dividend %- Quick Ratio4.80 Sales past 5Y- Gross Margin- 52W Low81.77% ATR0.17
Employees13 Current Ratio4.80 Sales Q/Q- Oper. Margin- RSI (14)49.97 Volatility4.76% 5.17%
OptionableYes Debt/Eq0.00 EPS Q/Q329.30% Profit Margin-64.40% Rel Volume0.26 Prev Close3.21
ShortableYes LT Debt/Eq0.00 EarningsAug 03 BMO Payout- Avg Volume737.18K Price3.29
Recom2.00 SMA20-0.47% SMA501.08% SMA200-43.37% Volume190,344 Change2.49%
Jun-08-20Reiterated H.C. Wainwright Buy $20 → $10
May-14-20Initiated BTIG Research Buy $23
Oct-02-19Reiterated Chardan Capital Markets Buy $17
Sep-25-19Initiated Chardan Capital Markets Buy $17
Sep-18-19Initiated William Blair Outperform
May-31-19Initiated H.C. Wainwright Buy
Sep-01-17Initiated Citigroup Buy $11
Mar-06-17Resumed Jefferies Buy $17
May-12-16Resumed Jefferies Buy
Oct-05-20 03:00PM  
Sep-14-20 10:20AM  
Sep-09-20 08:30AM  
Sep-02-20 08:30AM  
Aug-13-20 08:00AM  
Aug-05-20 09:30AM  
Aug-03-20 07:01PM  
07:30AM  
Jul-27-20 08:00AM  
Jul-01-20 08:00AM  
Jun-27-20 03:17PM  
Jun-22-20 08:47AM  
Jun-05-20 09:05AM  
Jun-02-20 09:00AM  
Jun-01-20 02:15PM  
08:00AM  
May-31-20 07:50AM  
May-29-20 04:50PM  
11:48AM  
10:31AM  
10:15AM  
09:20AM  
May-27-20 09:40AM  
May-26-20 11:41AM  
10:43AM  
May-25-20 06:41PM  
May-11-20 09:52AM  
08:41AM  
May-08-20 07:55AM  
May-04-20 06:30PM  
07:30AM  
Apr-27-20 08:30AM  
Apr-20-20 01:40PM  
Mar-28-20 02:49AM  
Mar-24-20 08:30AM  
Mar-19-20 10:50AM  
Mar-12-20 03:15PM  
Mar-09-20 07:30AM  
06:30AM  
Mar-02-20 08:30AM  
Feb-28-20 08:30AM  
Feb-17-20 11:15AM  
Feb-05-20 08:00AM  
Jan-06-20 08:00AM  
Dec-24-19 07:06AM  
Dec-19-19 03:07PM  
09:35AM  
07:52AM  
Dec-18-19 04:05PM  
Dec-17-19 07:47PM  
08:29AM  
Dec-04-19 04:05PM  
Nov-21-19 12:21AM  
Nov-14-19 08:30AM  
Nov-11-19 12:10AM  
Nov-04-19 07:30AM  
Oct-28-19 08:30AM  
Oct-18-19 09:37AM  
Oct-02-19 08:47AM  
Oct-01-19 04:43PM  
09:23AM  
08:49AM  
07:30AM  
Sep-26-19 04:10PM  
Sep-24-19 09:00AM  
Sep-23-19 11:46AM  
Sep-20-19 09:10AM  
Sep-19-19 09:38AM  
Sep-03-19 10:53AM  
Aug-09-19 03:08AM  
Aug-05-19 03:59PM  
07:30AM  
Jul-29-19 08:00AM  
Jul-04-19 11:36AM  
Jun-28-19 03:19PM  
Jun-24-19 11:00AM  
08:12AM  
07:30AM  
Jun-23-19 05:30PM  
Jun-12-19 08:30AM  
May-29-19 08:30AM  
May-13-19 11:01AM  
08:15AM  
May-10-19 09:29AM  
May-07-19 02:06PM  
May-06-19 12:00PM  
07:35AM  
07:30AM  
Apr-29-19 08:30AM  
Apr-11-19 08:30AM  
Mar-18-19 11:41AM  
08:30AM  
Mar-12-19 12:53PM  
07:46AM  
07:30AM  
Mar-05-19 08:00AM  
Feb-05-19 08:30AM  
Dec-20-18 11:32AM  
Nov-28-18 08:00AM  
Nov-21-18 08:30AM  
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of schizophrenia. The company is also developing seltorexant that has completed Phase IIb clinical trial for treating insomnia and major depressive disorders; and MIN-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the roluperidone worldwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VAN HEEK G JANDirectorSep 10Buy2.977,00020,79020,333Sep 11 05:13 PM
Ahlholm Frederick WSVP, Chief Accounting OfficerMay 26Sale15.008,339125,0856,884May 27 04:43 PM
Race GeoffEVP, CFO & CBODec 17Sale7.105,82641,365205,044Dec 17 04:48 PM
Luthringer RemyCEODec 17Sale7.102,41217,12549,040Dec 17 04:46 PM
Ahlholm Frederick WSVP, Chief Accounting OfficerDec 17Sale7.101,55711,05515,223Dec 17 04:45 PM
Reilly Joseph H.SVP & Chief Operating OfficerDec 17Sale7.102,72419,34026,225Dec 17 04:44 PM
Russell Richard E.PresidentDec 12Sale7.423,11323,09833,770Dec 13 04:07 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.